Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism

被引:143
作者
Baillie, Thomas A. [1 ]
机构
[1] Merck Res Labs, Dept Drug Metab & Pharmacokinet, West Point, PA 19486 USA
关键词
D O I
10.1021/tx7002273
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The science of drug metabolism and pharmacokinetics (DMPK) has developed significantly over the past 20 years, and its functional role in today's pharmaceutical industry has matured to the point where DMPK has become an indispensable discipline in support of drug discovery and development. While contributions to the lead optimization phase of discovery efforts have been particularly noteworthy in helping to select only the best drug candidates for entry into development, it should be recognized that the scope of DMPK spans the continuum of discovery through clinical evaluation and even into the post-marketing phase; as such, the breadth of DMPK's involvement is almost unique in contemporary pharmaceutical research. This perspective summarizes notable advances in the field, many of which have been made possible by technological developments in areas such as molecular biology, genetics, and bioanalytical chemistry, and highlights the critical nature of key partnerships between Drug Metabolism, Medicinal Chemistry, and Safety Assessment groups in attempting to advance drug candidates with a low potential for causing adverse events in humans. Finally, some speculative predictions are made of the future role of DMPK in pharmaceutical research, where current advances in our mechanistic understanding of the molecular processes that control the absorption, disposition, metabolism, elimination, and toxicity of drugs and their biotransformation products will combine to further enhance the impact of DMPK in drug discovery and development.
引用
收藏
页码:129 / 137
页数:9
相关论文
共 79 条
  • [1] Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: Application to studies on the biotransformation of Indinavir
    Anari, MR
    Sanchez, RI
    Bakhtiar, R
    Franklin, RB
    Baillie, TA
    [J]. ANALYTICAL CHEMISTRY, 2004, 76 (03) : 823 - 832
  • [2] Drug metabolites in safety testing
    Baillie, TA
    Cayen, MN
    Fouda, H
    Gerson, RJ
    Green, JD
    Grossman, SJ
    Klunk, LJ
    LeBlanc, B
    Perkins, DG
    Shipley, LA
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2002, 182 (03) : 188 - 196
  • [3] Future of toxicology-metabolic activation and drug design: Challenges and opportunities in chemical toxicology
    Baillie, Thomas A.
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (07) : 889 - 893
  • [4] MSE with mass defect filtering for in vitro and in vivo metabolite identification
    Bateman, Kevin P.
    Castro-Perez, Jose
    Wrona, Mark
    Shockcor, John P.
    Yu, Kate
    Oballa, Renata
    Nicoll-Griffith, Deborah A.
    [J]. RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2007, 21 (09) : 1485 - 1496
  • [5] American college of clinical pharmacology position statement on the use of microdosing in the drug development process
    Bertino, Joseph S., Jr.
    Greenberg, Howard E.
    Reed, Michael D.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (04) : 418 - 422
  • [6] Impact of pharmacometric reviews on new drug approval and labeling decisions - a survey of 31 new drug applications submitted between 2005 and 2006
    Bhattaram, V. A.
    Bonapace, C.
    Chilukuri, D. M.
    Duan, J. Z.
    Garnett, C.
    Gobburu, J. V. S.
    Jang, S. H.
    Kenna, L.
    Lesko, L. J.
    Madabushi, R.
    Men, Y.
    Powell, J. R.
    Qiu, W.
    Ramchandani, R. P.
    Tornoe, C. W.
    Wang, Y.
    Zheng, J. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) : 213 - 221
  • [7] Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer
    Bosch, TM
    Meijerman, I
    Beijnen, JH
    Schellens, JHM
    [J]. CLINICAL PHARMACOKINETICS, 2006, 45 (03) : 253 - 285
  • [8] Applications of accelerator mass spectrometry for pharmacological and toxicological research
    Brown, K
    Tompkins, EM
    White, INH
    [J]. MASS SPECTROMETRY REVIEWS, 2006, 25 (01) : 127 - 145
  • [9] Increasing throughput and information content for in vitro drug metabolism experiments using ultra-performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer
    Castro-Perez, J
    Plumb, R
    Granger, JH
    Beattie, L
    Joncour, K
    Wright, A
    [J]. RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2005, 19 (06) : 843 - 848
  • [10] ABCB1 pharmacogenetics:: Progress, pitfalls, and promise
    Chinn, L. W.
    Kroetz, D. L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) : 265 - 269